_55_3_525_540

Psychiatr. Pol. 2021; 55(3): 525–540

 

Natalia Śmierciak, Wirginia Krzyściak, Marta Szwajca, Amira Bryll,
 
Tadeusz Popiela, Paulina Karcz, Maciej Pilecki

FREE POLISH FULLTEXT:
 

FREE ENGLISH FULLTEXT:

Summary
Objectives. Cardiometabolic syndromes are the most common causes of complications shortening life expectancy in patients treated for mental disorders, especially schizophrenia. However, how much cardiometabolic risk is related to lifestyle, side-effects of treatment or psychosis is not clear. The aim of this study was a prospective assessment of metabolic changes in young, initially somatically healthy patients diagnosed with the first acute episode of psychosis with no prior pharmacological treatment.
Methods. The study involved 15 young patients (average age of 19.95 ± 6.88 years). Analyses (laboratory and clinical) were performed at the time of admission and after 3 and 12 weeks and included morphology, lipid profile, glucose, inflammation markers, blood pressure (BP), and body mass index (BMI). The severity of clinical symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS), and the cognitive functioning was assessed using the Montreal Cognitive Assessment (MoCA). The duration of untreated psychosis (DUP) was also measured.
Results. There was a significant increase in BMI, dyslipidemia, inflammation, and systolic blood pressure after 12 weeks from the start of the treatment, while cortisol level decreased. A negative correlation was observed between PANSS-P (PANSS positivescale) measurements and total cholesterol, PANSS total and low-density lipoprotein, as well as DUPand MoCA. High-density lipoprotein (HDL) correlated positively with DUP, cortisol, monocytes, and white blood cells in the first week.
Conclusions. The results of the study indicate a relationship between the development and treatment of the first acute episode of psychosis and the results of laboratory tests that are indicators of the development of metabolic stress in patients.


ISSN 0033-2674 (PRINT)

ISSN 2391-5854 (ONLINE)


Psychiatria Polska
is an Open Access journal:
Creative Commons: CC-BY
SHERPA RoMEO:
Blue


Zadanie finansowane
w ramach umowy
nr 739/P-DUN/2018
ze środków MNiSW
przeznaczonych
na działalność
upowszechniającą naukę


KRW PTP dziękuje 
firmie PPL – Koral – J.Koral sp.j.
za wsparcie finansowe 
udzielone w 2020 roku



Inne strony PTP:
Other PTP websites:

www.psychiatria.org.pl
www.psychiatriapsychoterapia.pl

www.archivespp.pl
www.psychoterapiaptp.pl

Psychiatria Polska
INDEXED IN:
Thomson Reuters Master List
Science Citation Index Expanded
Journal Citation Reports
(Impact Factor 1,657)

Medline/Index Medicus
PubMed/LinkOut
MNiSW (40 pkt)
Scopus/SCImago
CiteScore 2,4
(SJR 0,414; SNIP 0,707)
EMBASE/Excerpta Medica
PsycINFO, EBSCO,
Index Copernicus
Erih Plus, Cochrane Library
CrossRef/DOI

We recommend:

Pharmacological Reports

 


KONTAKT Z REDAKCJĄ - wyłącznie e-mail: redakcja@psychiatriapolska.pl 

Biuro KRW PTP - prenumeraty, faktury - wyłącznie e-mail: biuro@krwptp.pl 
krwptp.pl